Sherry Taylor Ph.D. 1986-1990
The molecular analysis of mutations of the human factor IX gene
Currently: Director, Molecular Diagnostic Laboratory, St. John Hospital, New Brunswick

Elizabeth Murray M.Sc. 1987-1989
The genetics of von Willebrand's disease
Currently: Research Group Leader, Biotechnology Company, Calgary

David Picketts Ph.D. 1990-1993
Structure and function relationships of factor IX
Currently: Associate Professor, University of Ottawa

Elizabeth Murray Ph.D. 1989-1994
Molecular studies of the interactions of von Willebrand factor with platelet glycoprotein Ib
Currently: Research Group Leader, Biotechnology Company, Calgary

Lesley McGlynn M.Sc. 1992-1994
Transcriptional regulation of the Factor VIII gene
Currently: Senior supervisory molecular genetic technologist, Hospital for Sick Children

Lara Boccia M.Sc. 1992-1994
An analysis of the upstream promoter elements of the factor IX gene
Currently: Biotechnology Technologist

Susan Kerr M.Sc. 1991-1996
A molecular study of the platelet glycoprotein Ib/IX complex
Currently: Life Insurance Executive

Jolene Brady M.Sc. 1994-1996
The role of androgens and distal regulatory elements on expression of factor IX.
Currently: Physician

Kimberley Wynd M.Sc. 1996-1998
Receptor-mediated delivery of factor VIII transgenes to hepatocytes.
Currently: Physician

Kelly Wilton M.Sc. 1996-1998
Factors influencing the phenotype of hemophilia B Leyden.
Currently: High School Biology Teacher, London, ON

Carla Cuthbert Ph.D. 1994-2000
Megakaryocytic differentiation and von Willebrand factor expression
Currently: Clinical Chemist, Florida, USA

Angela Keightley Ph.D. 1995-2000
The control of endothelial cell expression of von Willebrand factor
Currently: Research Scientist, Montreal

Megan Begbie Ph.D. 1995-1999
Factors influencing transcriptional activation of the factor VIII and IX genes
Currently: Scientist, Health Canada, Ottawa, ON

Brian Brown Ph.D. 1998-2003
Evaluation of gene therapy strategies for hemophilia A
Currently: Assistant Professor, Mount Sinai Medical Centre, New York City, NY

Annie Killoran M.Sc. 1999-2001
Non-viral delivery of canine factor VIII transgenes for hemophilia gene therapy
Currently: Physician

Lee O’Brien Ph.D. 2000-2004
Factors influencing the biosynthetic efficiency of von Willebrand factor by endothelial cells
Currently: Research Scientist, Eli Lilly, USA

Fiona Rawle (nee Grant) Ph.D. 2000-2005
Immunologic responses to factor VIII gene therapy
Currently: Lecturer, McMaster University

Stephanie Van der Pol M.Sc. 2004-2005
Tolerance induction to FVIII through tolerogenic antigen presentation
Currently: Physiotherapist

Cyndi Pruss Ph.D. 2004-2010
The role of von Willebrand factor in arterial thrombosis
Currently: Assistant Professor, Department of Biomedical and Molecular Sciences, Queen's University

Mohammad Quadura Ph.D. 2005-2008
Induction of immunologic tolerance to factor VIII
Currently: Scientist at the Keenan Research Centre for Biomedical Science of St. Michael's Hospital and an Assistant Professor at the University of Toronto and Staff Surgeon in the Division of Vascular Surgery at St. Michael's Hospital.

Braden Waters Ph.D. 2006-2010
Mechanisms of immunologic tolerance to Factor VIII

Mia Golder Ph.D. 2006-2010
The role of Factor VIII and von Willebrand factor in arterial thrombosis
Currently: Manager of Research and Training Programs, Canadian Blood Services

Jacob Riches M.Sc. 2009-2012
Endothelial cell differentiation and the synthesis of FVIII and VWF

Meghan Deforest M.Sc. 2011-2013
Generation and optimization of the Self-Administered Bleeding Assesment Tool

Mackenzie Bowman Ph.D. 2008-2013
Investigating the genetic basis of type 3 von Willebrand disease

Jane Young M.Sc. 2013-2015
Validation of the Self-BAT (Self-Administered Bleeding Assessment Tool) and evaluation of determinants of health in Hemophilia carriers

Lara Casey, M.Sc. 2013 - 2015
Investigating the dysregulation of angiogenesis in type 2 von Willebrand Disease (VWD) in blood outgrowth endothelial cells

Lindsey Hawke, Ph.D. 2010 - 2015
The Effect of Variant VWF Splicing on Quantitative and Qualitative Variants of VWD

Silvia Albanez Ph.D. 2010 - 2015
Evaluation of the age-related pathophysiology of von Willebrand factor
Currently: Medical Science Liaison, The Janssen Pharmaceutical company

Jackie Leonard M.Sc. 2012 - 2016
The effect of biomechanical and biochemical regulators on the expression of Factor VIII and von Willebrand Factor in endothelial cells
Currently: Genetic Counsellor, Children's Hospital of Pennsylvania

Jesse Lai, PhD 2013-2017
Early mechanisms of FVIII immunity in Hemophilia A

Victoria Candy, MSc 2015-2017
Evaluation of the determinants and characterization of bleeding in Hemophilia A and B carriers

Soundarya Selvam, PhD 2014-2018
Investigating the role of von Willebrand factor (VWF) in angiogenesis

POST DOCTORAL FELLOWS

Seiki Kamisue PDF 1994-1996
Characterization of a canine model of hemophilia A
Currently: Faculty, Nara College of Medicine, Japan

Christine Hough PDF 1996-1998
Definition of a canine model of hemophilia A
Currently: Adjunct Assistant Professor, Queen’s University

Kirsty Tompkins PDF 1998-1999
The platelet adhesive genotype and unstable angina
Currently: Associate Professor, Department of Medicine, Memorial University

Maha Othman PDF 2001-2002 & 2003-2005
Genetic variability of the collagen binding domain of von Willebrand Factor
Currently: Lecturer, St. Lawrence College, Kingston

Paula James PDF 2002-2004
Molecular genetic basis of type 1 von Willebrand disease
Currently: Professor, Department of Medicine, Queen’s University

Masaru Shibata PDF 2002-2005
Development of a lentiviral-based system for hemophilia gene therapy.
Currently: Faculty, Department of Pediatrics, Nara College of Medicine, Japan

Ergul Berber PDF 2002-2005
Biosynthetic defects of von Willebrand factor
Currently: Assistant Professor, Halic University, Istanbul, Turkey

Hideto Matsui PDF 2005-2009
Stem cell-based gene therapy for hemophilia A
Currently: Faculty, Department of Pediatrics, Nara College of Medicine, Japan

Rouzbeh Chegeni PDF 2005-2008
Gene transfer for von Willebrand disease
Currently: Senior Clinical Scientist, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Margareth Ozello PDF 2006-2010
Ex vivo gene transfer for hemophilia A
Currently: Senior Clinical Hematologist, University of Campinas, Brazil

Yasuaki Shida PDF 2010-2013
The role of von Willebrand factor and ADAMTS13 in thrombosis and hemostasis
Currently: Assistant Professor, Department of Pediatrics, Nara Medical University, Japan

Kenichi Ogiwara PDF 2013 - 2015
Characterizing mechanisms that regulate FVIII pharmacokinetics and VWF-FVIII clearance
Currently: Faculty, Department of Pediatrics, Nara Medical University, Japan

Philip Zakas, PDF 2016-2018
Molecular evolution of mammalian von Willebrand factor by ancestral sequence reconstruction and Gene delivery of large nucleic acid cassettes via foamy viral vectors for the treatment of hemophilia A
Currently: Scientist, Sanofi

Matteo Zago-Schmitt, MSc 2017-2019
Evaluation of the hemostatic stress response in Type 1 von Willebrand Disease

Crystal Choi, MSc 2018-2020
The Role of von Willebrand Factor in the Pathogenesis of Deep Vein Thrombosis in Acute Inflammation

Page Last Updated: 2020 August 27